Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: A retrospective study

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2743-2746

  Saif, Muhammad Wasif ^a   Kaley, Kristin ^b   Brennan, Marianne ^b   Garcon, Marie Carmel ^c   Rodriguez, Gladys ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

Author keywords

Capecitabine; Chemotherapy; Colon cancer; Fluorouracil; Mitomycin C

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MITOMYCIN; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; AGED; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; MALE; METASTATIC COLORECTAL CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; ARTICLE; CHEMOTHERAPY; COLON CANCER; COLORECTAL TUMOR; DISEASE COURSE; DRUG RESISTANCE; METASTASIS; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME;

CAPECITABINE; CHEMOTHERAPY; COLON CANCER; FLUOROURACIL; MITOMYCIN-C;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84881336520     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin 63(1): 11-30, 2013.
2. Saif MW and Chu E: Biology of colorectal cancer. Cancer J 16(3): 196-201, 2010.
3. Saif MW, Kaley K, Penney R, Hotchkiss S, Syrigos KN and Strimpakos AS: The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): A single institution experience. Anticancer Res 31(9): 2971-2974, 2011.
4. Iyer VN and Szybalski W: A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc Natl Acad Sci USA 50: 355-362, 1963.
5. Saif MW, Shi N and Zelt S: Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 15(35): 4415-4422, 2009.
6. Tanabe M, Ito Y, Tokudome N Sugihara T, Miura H, Takahashi S, Seto Y, Iwase T and Hatake K: Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer 16(4): 301-306, 2009.
7. Berghmans T, Gourcerol D, Lafitte JJ, Kotsori K, Paesmans M, Scherpereel A, Leclercq N and Sculier JP: European Lung Cancer Working Party: Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: A prospective study. Lung Cancer 61: 378-384, 2008.
8. Horvath A and Mostafid H: Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. BJU Int 103: 726-729, 2009.
9. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L and Murray K: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14: 2527-2539, 1996.
10. Yer VN and Szybalski W: Mitomycins and porfiromycin: Chemical mechanism of activation and cross-linking of DNA. Science 145: 55-58, 1964.
11. Cantrell JE Jr., Phillips TM and Schein PS: Carcinomaassociated hemolytic-uremic syndrome: A complication of mitomycin C chemotherapy. J Clin Oncol 3: 723-734, 1985.
12. Ogata Y, Matono K, Sasatomi T, Ishibashi N, Torigoe S, Fukumitsu T, Mizobe T, Yamashita N, Yanagawa T and Shirouzu K: Up-regulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C. J Surg Oncol 93(1): 47-55, 2006.
13. Franchi F, Barone C, Seminara P, Codacci-Pisanelli G, Codacci-Pisanelli M, Ferri GM, Garufi C, Grieco A and Pagani V: 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. Med Oncol Tumor Pharmacother 8: 75-78, 1991.
14. http://ctep.cancer.gov/protocolDevelopment/electronic-Applications/ctc. htm
15. Therasse, P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Nat Can Inst 92(3): 205-216, 2000.
16. Hofheinz RD, Hartmann JT, Willer A, Oechsle K, Hartung G, Gnad U, Saussele S, Kreil S, Bokemeyer C, Hehlmann R and Hochhaus A: Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: Results of an extended multicentre phase-I trial. Br J Cancer 91: 834-838, 2004.
17. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK and Park K: Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: A phase II study. Cancer Chemother Pharmacol. 56: 10-14, 2005.
18. Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J and Shellito P: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer. 91: 839-843, 2004.
19. Harba A, Jordan K and Kegel R: Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (ACRC). ASCO Annual Meeting. Abstract No: 1335, 2003.
20. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J and Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 93: 510-514, 2005.
21. Watkins D, Rao S, Cunningham D, Hill M, Price T, Norman A, Tebbutt N and Shellito P: Capecitabine and mitomycin-C: An active low toxicity first line. ASCO Annual Meeting. Abstract No: 1109, 2003.
22. Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J and Price T: International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. ASCO Annual Meeting. Abstract No: 4023, 2009.
23. Dimou A, Syrigos KN and Saif MW: Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opin Investig Drugs 19(6): 723-735, 2010.
24. Maisano R, Caristi N, Mare M, Raffaele M, Iorfida M, Mafodda A, Zavettieri M and Nardi M: Mitomycin C plus capecitabine (MIXE) in anthracycline-And taxane-pretreated metastatic breast cancer. A multicenter phase II study. Anticancer Res 27: 2871-2875, 2007.
25. Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi MB, Zepponi L, Santini D, Tonini G and Burattini L: Capecitabine and mitomycin C is an effective combination for anthracyclineand taxane-resistant metastatic breast cancer. Oncology 70(4): 294-300, 2006.
26. Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Kohne CH, Kafer G, Kanz L and Bokemeyer C: Protracted infusional 5-fluorouracil plus highdose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: A phase I/II dose escalation study. Br J Cancer 89: 2051-2056, 2003.
27. Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J and Cunningham D: Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 3: 235-242, 2004.